MPA treatment overview: induction, maintenance and plasma exchange
This page explains what each treatment does and why. It does not give doses or recommend a treatment; your specialist tailors treatment to you.
Every medical claim on this page links to its source. Last updated 15 November 2026. Educational information, not medical advice.
Two phases
- Induction calms active inflammation. For organ-threatening disease this generally means rituximab or cyclophosphamide, together with glucocorticoids (steroids).1 Very severe kidney disease can affect which approach is chosen.
- Maintenance keeps MPA quiet after remission. It may include rituximab or azathioprine. KDIGO suggests a general maintenance range of 18 months to four years after induction.1,2
What each medicine group does
| Medicine | What it does | Things to ask about |
|---|---|---|
| Rituximab | Removes B cells, immune cells involved in making antibodies.3 | Infection risk, antibody (immunoglobulin) levels, hepatitis B screening, vaccine timing.1,3 |
| Cyclophosphamide | A strong immune-suppressing medicine. | Fertility effects and preservation options, bladder and long-term cancer risks.1,4 |
| Glucocorticoids (steroids) | Reduce inflammation quickly. | Bones, blood pressure, blood sugar, sleep and mood. Steroids page. |
| Azathioprine | An option for maintenance.2 | Blood count monitoring. |
Reduced steroid exposure has randomized-trial support in severe AAV.5,1 Ask whether your plan includes preventive medicine against Pneumocystis pneumonia and how infections will be watched for.1
Plasma exchange
Plasma exchange removes and replaces the liquid part of blood. KDIGO supports considering it in selected patients, for example with rapidly worsening kidney function, a need for dialysis, or lung bleeding with low oxygen, and it is specifically indicated when anti-GBM disease is also present.1,5
A note on avacopan (Tavneos)
Avacopan's regulatory status changed in 2026. See avacopan: where things stand. Do not stop or change any medicine without talking to your prescriber.
For researchers and clinicians
RAVE established rituximab as an alternative to cyclophosphamide for severe AAV induction in its population; RITUXVAS studied severe renal AAV with some cyclophosphamide in the rituximab arm. PEXIVAS tested reduced-dose glucocorticoids and plasma exchange in severe AAV. MAINRITSAN and RITAZAREM support scheduled rituximab maintenance; in RITAZAREM (170 randomized patients with relapsing AAV) relapse hazard was lower with rituximab than azathioprine (HR 0.41, 95% CI 0.27–0.61).6,5,2,1 BREVAS (belimumab added to azathioprine) did not significantly reduce relapse.7
Sources
- KDIGO: KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis [doc ref 1]
- Annals of the Rheumatic Diseases (2023): RITAZAREM: rituximab versus azathioprine for maintenance in relapsing AAV [doc ref 39]
- DailyMed (NLM): Rituxan (rituximab) U.S. prescribing information [doc ref 37]
- American College of Rheumatology: ACR guideline for the management of reproductive health in rheumatic and musculoskeletal diseases [doc ref 5]
- New England Journal of Medicine (2020): PEXIVAS: plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [doc ref 17]
- Frontiers in Pharmacology (2024): Biological agents in the treatment of ANCA-associated vasculitis (review of pivotal trials) [doc ref 38]
- Arthritis & Rheumatology (2019): BREVAS: belimumab and azathioprine for maintenance of remission in AAV [doc ref 42]
Links checked 15 November 2026. Full list: all sources.